losartan has been researched along with Focal Segmental Glomerulosclerosis in 23 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to evaluate the effects of losartan on proteinuria and renal function in patients with FSGS refractory to immunosuppressive treatment." | 9.10 | Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2003) |
| " The aim of this study was to evaluate the effects of losartan on proteinuria and renal function in patients with FSGS refractory to immunosuppressive treatment." | 5.10 | Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2003) |
| "We report three cases of focal glomerular sclerosis (FGS) with proteinuria that improved with the administration of angiotensin type 1 receptor blocker (ARB, losartan or valsartan)." | 3.72 | [Angiotensin type 1 receptor blocker reduced proteinuria in patients of focal glomerular sclerosis]. ( Chihara, Y; Fujimori, T; Iidaka, K; Inada, H; Ishimitsu, T; Matsuoka, H; Ogihara, T; Ono, H; Ono, Y; Rakugi, H; Ueda, Y, 2004) |
| " Both captopril treatment and losartan treatment completely blocked the development of hypertension in diabetic SHR." | 3.69 | Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. ( Abe, K; Fu, LP; Kanazawa, M; Kohzuki, M; Obara, K; Saito, T; Yasujima, M; Yoshida, K, 1995) |
| "The Novel Therapies for Resistant Focal Segmental Glomerulosclerosis (FONT) project is a multicenter Phase I/II RCT designed to investigate the potential efficacy of novel therapies for resistant FSGS." | 2.76 | Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. ( Gassman, J; Gipson, D; Greene, T; Joy, M; Pinsk, M; Savin, V; Somers, M; Trachtman, H; Vento, S; Wickman, L, 2011) |
| "The rat model of diabetic nephropathy was established by streptozotozin(STZ) injection, and the rats were randomly divided into 3 groups: (a normal group, a model group and a losartan group)." | 1.35 | [The effect of losartan on glomerular sclerosis in rats with diabetic nephropathy]. ( Liu, JS; Ning, WB; Tao, LJ; Wang, L; Xu, JY, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| van Thiel, BS | 1 |
| van der Linden, J | 1 |
| Ridwan, Y | 1 |
| Garrelds, IM | 1 |
| Vermeij, M | 1 |
| Clahsen-van Groningen, MC | 1 |
| Qadri, F | 1 |
| Alenina, N | 1 |
| Bader, M | 1 |
| Roks, AJM | 1 |
| Danser, AHJ | 1 |
| Essers, J | 1 |
| van der Pluijm, I | 1 |
| Toba, H | 1 |
| Ikemoto, MJ | 1 |
| Kobara, M | 1 |
| Nakata, T | 1 |
| Shiozaki, Y | 1 |
| Fujikura, T | 1 |
| Isobe, S | 1 |
| Takatsuka, I | 1 |
| Sato, T | 1 |
| Goto, D | 1 |
| Ishigaki, S | 1 |
| Ohashi, N | 1 |
| Yasuda, H | 1 |
| Awazu, M | 1 |
| Yamada, M | 1 |
| Asada, N | 1 |
| Hashiguchi, A | 1 |
| Kosaki, K | 1 |
| Matsumura, K | 1 |
| Ávila, VF | 1 |
| Foresto-Neto, O | 1 |
| Arias, SCA | 1 |
| Faustino, VD | 1 |
| Malheiros, DMAC | 1 |
| Camara, NOS | 1 |
| Zatz, R | 3 |
| Fujihara, CK | 3 |
| Kocyigit, I | 1 |
| Dortdudak, S | 1 |
| Eroglu, E | 1 |
| Unal, A | 1 |
| Sipahioglu, MH | 1 |
| Berk, V | 1 |
| Tokgoz, B | 1 |
| Oymak, O | 1 |
| Fervenza, FC | 1 |
| Perazella, MA | 1 |
| Choi, MJ | 1 |
| Xu, JY | 1 |
| Tao, LJ | 1 |
| Wang, L | 1 |
| Ning, WB | 1 |
| Liu, JS | 1 |
| Gupta, A | 1 |
| Gaikwad, J | 1 |
| Khaira, A | 1 |
| Rana, DS | 1 |
| Trachtman, H | 1 |
| Vento, S | 1 |
| Gipson, D | 1 |
| Wickman, L | 1 |
| Gassman, J | 1 |
| Joy, M | 1 |
| Savin, V | 1 |
| Somers, M | 1 |
| Pinsk, M | 1 |
| Greene, T | 1 |
| Grosch, S | 1 |
| Van Overmeire, L | 1 |
| Krzesinski, JM | 1 |
| Bovy, C | 1 |
| Saeed, B | 1 |
| Mazloum, H | 1 |
| Askar, M | 1 |
| Yuan, SG | 1 |
| Liu, RH | 1 |
| Xia, YC | 1 |
| Bertram, D | 1 |
| Blanc-Brunat, N | 1 |
| Sassard, J | 1 |
| Lo, M | 1 |
| Usta, M | 1 |
| Ersoy, A | 1 |
| Dilek, K | 1 |
| Ozdemir, B | 1 |
| Yavuz, M | 1 |
| Güllülü, M | 1 |
| Yurtkuran, M | 1 |
| Aunapuu, M | 1 |
| Pechter, U | 1 |
| Arend, A | 1 |
| Suuroja, T | 1 |
| Ots, M | 1 |
| Kim, HJ | 1 |
| Ryu, JH | 1 |
| Han, SW | 1 |
| Park, IK | 1 |
| Paik, SS | 1 |
| Park, MH | 1 |
| Paik, DJ | 1 |
| Chung, HS | 1 |
| Kim, SW | 1 |
| Lee, JU | 1 |
| Chihara, Y | 1 |
| Ono, H | 1 |
| Ono, Y | 1 |
| Inada, H | 1 |
| Ueda, Y | 1 |
| Fujimori, T | 1 |
| Iidaka, K | 1 |
| Ishimitsu, T | 1 |
| Rakugi, H | 1 |
| Ogihara, T | 1 |
| Matsuoka, H | 1 |
| Ji, Z | 1 |
| Huang, C | 1 |
| Liang, C | 1 |
| Chen, B | 1 |
| Chen, S | 1 |
| Sun, W | 1 |
| Malheiros, DM | 1 |
| De Nucci, G | 1 |
| Kohzuki, M | 1 |
| Yasujima, M | 1 |
| Kanazawa, M | 1 |
| Yoshida, K | 1 |
| Fu, LP | 1 |
| Obara, K | 1 |
| Saito, T | 1 |
| Abe, K | 1 |
| Bidani, AK | 1 |
| Griffin, KA | 1 |
| Bakris, G | 1 |
| Picken, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Novel Therapies for Resistant Focal Segmental Glomerulosclerosis[NCT00814255] | Phase 2 | 32 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System[NCT02235857] | 35 participants (Anticipated) | Interventional | 2015-05-03 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with a reduction in proteinuria at 6 months by > 50% of the value at screening AND stable GFR defined as greater than 75 ml/min/1.73m2 in those with an initial value above 90 OR within 25% of baseline for remaining patients. (NCT00814255)
Timeframe: baseline and 6 months
| Intervention | participants (Number) |
|---|---|
| Conservative Medical Therapy Plus Adalimumab | 0 |
| Conservative Medical Therapy (Lisinopril, Losartan, Atorvastat | 2 |
| Conservative Medical Therapy Plus Galactose | 2 |
(NCT00814255)
Timeframe: Up to 7 months
| Intervention | participants (Number) |
|---|---|
| Conservative Medical Therapy Plus Adalimumab | 7 |
| Conservative Medical Therapy (Lisinopril, Losartan, Atorvastat | 7 |
| Conservative Medical Therapy Plus Galactose | 7 |
2 trials available for losartan and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2011 |
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2011 |
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2011 |
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2011 |
Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment.
Topics: Adrenal Cortex Hormones; Adult; Antihypertensive Agents; Azathioprine; Blood Pressure; Cyclophospham | 2003 |
21 other studies available for losartan and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
In Vivo Renin Activity Imaging in the Kidney of Progeroid
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; DNA | 2021 |
Secreted protein acidic and rich in cysteine (SPARC) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1) increments by the renin-angiotensin system induce renal fibrosis in deoxycorticosterone acetate-salt hypertensive rats.
Topics: ADAMTS1 Protein; Angiotensin II Type 1 Receptor Blockers; Animals; Desoxycorticosterone Acetate; Ext | 2022 |
Case report: increased single-nephron estimated glomerular filtration rate in an adult patient with low birth weight.
Topics: Angiotensin II Type 1 Receptor Blockers; Cell Count; Female; Glomerular Filtration Rate; Glomerulosc | 2020 |
A girl with a mutation of the ciliary gene CC2D2A presenting with FSGS and nephronophthisis.
Topics: Child; Child, Preschool; Cytoskeletal Proteins; Female; Fibrosis; Glomerulosclerosis, Focal Segmenta | 2022 |
Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Female; G | 2019 |
Immunoglobulin A nephropathy could be a clue for the recurrence of gastric adenocarcinoma.
Topics: Adenocarcinoma; Bone Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Edema; Glomerulonephri | 2013 |
American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antibodies, Monoclonal, Mur | 2014 |
[The effect of losartan on glomerular sclerosis in rats with diabetic nephropathy].
Topics: Animals; Collagen Type IV; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabeti | 2008 |
Marfan syndrome and focal segmental glomerulosclerosis: a novel association.
Topics: Adolescent; Adrenal Cortex Hormones; Antihypertensive Agents; Fibrillins; Follow-Up Studies; Glomeru | 2010 |
[Fibrillary nonamyloid glomerulonephritis: a rare etiology of nephrotic syndrome].
Topics: Coloring Agents; Complement C3; Congo Red; Diagnosis, Differential; Edema; Female; Fluorobenzenes; G | 2011 |
Spontaneous remission of post-transplant recurrent focal and segmental glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Child; Disease Pr | 2011 |
[Effects on ang II receptor antagonist on experimental glomerulosclerosis].
Topics: Angiotensin Receptor Antagonists; Animals; Blood Urea Nitrogen; Glomerulosclerosis, Focal Segmental; | 2000 |
Differential evolution of blood pressure and renal lesions after RAS blockade in Lyon hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; | 2002 |
Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Ba | 2003 |
Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2004 |
[Angiotensin type 1 receptor blocker reduced proteinuria in patients of focal glomerular sclerosis].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diet, Protein-Restricted; D | 2004 |
Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Seq | 2005 |
Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Diuretics | 2007 |
Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy.
Topics: Amino Acid Oxidoreductases; Angiotensin Receptor Antagonists; Animals; Arginine; Biphenyl Compounds; | 1995 |
Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Captopril; Diabetes M | 1995 |
Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pres | 2000 |